Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality

American Heart Journal

Volumn 170, Issue 2, 2015, Pages 380-389.e4

  Parrinello, Christina M ^a   Lutsey, Pamela L ^b   Ballantyne, Christie M ^c   Folsom, Aaron R ^b   Pankow, James S ^b   Selvin, Elizabeth ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HIGH SENSITIVITY C REACTIVE PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; ARTICLE; BLACK PERSON; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; INCIDENCE; METABOLISM; MULTICENTER STUDY; PHOTOMETRY; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE; TIME; TRENDS; UNITED STATES;

BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMORBIDITY; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 84939562013     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2015.04.017     Document Type: Article

References (44)

1. M.Y. Donath, and S.E. Shoelson Type 2 diabetes as an inflammatory disease Nat Rev Immunol 11 2 2011 98 107 10.1038/nri2925
2. G.S. Hotamisligil Inflammation and metabolic disorders Nature 444 7121 2006 860 867 10.1038/nature05485
3. F. Montecucco, and F. Mach New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor Clin Interv Aging 3 2 2008 341 349
4. S.D. De Ferranti, and N. Rifai C-reactive protein: a nontraditional serum marker of cardiovascular risk Cardiovasc Pathol 16 1 2007 14 21 10.1016/j.carpath.2006.04.006
5. T.A. Pearson, G.A. Mensah, R.W. Alexander, and et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 3 2003 499 511 10.1161/01.CIR.0000052939.59093.45
6. D.I. Buckley, R. Fu, M. Freeman, and et al. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force Ann Intern Med 151 7 2009 483 495
7. J. Danesh, R. Collins, P. Appleby, and et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies JAMA 279 18 1998 1477 1482
8. O.W. Oluleye, A.R. Folsom, V. Nambi, and et al. Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality Ann Epidemiol 23 2 2013 66 73 10.1016/j.annepidem.2012.11.004
9. S. Ahmadi-Abhari, R.N. Luben, N.J. Wareham, and et al. Seventeen year risk of all-cause and cause-specific mortality associated with C-reactive protein, fibrinogen and leukocyte count in men and women: the EPIC-Norfolk study Eur J Epidemiol 28 7 2013 541 550 10.1007/s10654-013-9819-6
10. A. Dregan, J. Charlton, P. Chowienczyk, and et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study Circulation 2014 10.1161/CIRCULATIONAHA.114.009990
11. I. Kardys, A.M. Knetsch, G.S. Bleumink, and et al. C-reactive protein and risk of heart failure. The Rotterdam Study Am Heart J 152 3 2006 514 520 10.1016/j.ahj.2006.02.023
12. W. Bekwelem, P.L. Lutsey, L.R. Loehr, and et al. White blood cell count, C-reactive protein, and incident heart failure in the Atherosclerosis Risk in Communities (ARIC) Study Ann Epidemiol 21 10 2011 739 748 10.1016/j.annepidem.2011.06.005
13. X. Wang, W. Bao, J. Liu, and et al. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis Diabetes Care 36 1 2013 166 175 10.2337/dc12-0702
14. B.B. Duncan, M.I. Schmidt, J.S. Pankow, and et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study Diabetes 52 7 2003 1799 1805
15. J.I. Barzilay, L. Abraham, S.R. Heckbert, and et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study Diabetes 50 10 2001 2384 2389
16. D.J. Freeman, J. Norrie, M.J. Caslake, and et al. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study Diabetes 51 5 2002 1596 1600
17. F.B. Hu, J.B. Meigs, T.Y. Li, and et al. Inflammatory markers and risk of developing type 2 diabetes in women Diabetes 53 3 2004 693 700
18. D.E. Laaksonen, L. Niskanen, K. Nyyssönen, and et al. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men Diabetologia 47 8 2004 1403 1410 10.1007/s00125-004-1472-x
19. S. Liu, L. Tinker, Y. Song, and et al. A prospective study of inflammatory cytokines and diabetes mellitus in a multiethnic cohort of postmenopausal women Arch Intern Med 167 15 2014 1676 1685 10.1001/archinte.167.15.1676
20. A.D. Pradhan, J.E. Manson, N. Rifai, and et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus JAMA 286 3 2001 327 334
21. A. Dehghan, I. Kardys, M.P.M. de Maat, and et al. Genetic variation, C-reactive protein levels, and incidence of diabetes Diabetes 56 3 2007 872 878 10.2337/db06-0922
22. P.M. Ridker, N.P. Paynter, N. Rifai, and et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men Circulation 118 22 2008 2243 2251 10.1161/CIRCULATIONAHA.108.814251 [4p following 2251]
23. P.M. Ridker, E. Danielson, F.A.H. Fonseca, and et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 21 2008 2195 2207 10.1056/NEJMoa0807646
24. J. Perk, G. De Backer, H. Gohlke, and et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 13 2012 1635 1701 10.1093/eurheartj/ehs092
25. J. Genest, R. Mcpherson, J. Frohlich, and et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 25 10 2009 567 579
26. G.L. Myers, R.H.M. Christenson, M. Cushman, and et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease Clin Chem 55 2 2009 378 384 10.1373/clinchem.2008.115899
27. D.C. Goff, D.M. Lloyd-Jones, G. Bennett, and et al. ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2013 2013 63(25) 10.1016/j.jacc.2013.11.005
28. F. Wensley, P. Gao, S. Burgess, and et al. Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data BMJ 342 2011 d548 10.1136/bmj.d548
29. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators Am J Epidemiol 129 4 1989 687 702
30. C.M. Parrinello, M.E. Grams, D. Couper, and et al. Recalibration of Blood Analytes over 25 Years in the Atherosclerosis Risk in Communities Study:Impact of Recalibration on Chronic Kidney Disease Prevalence and Incidence Clin Chem 2015 238873 [Epub ahead of print]
31. A.D. White, A.R. Folsom, L.E. Chambless, and et al. Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience J Clin Epidemiol 49 2 1996 223 233
32. W.D. Rosamond, A.R. Folsom, L.E. Chambless, and et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort Stroke 30 4 1999 736 743 10.1161/01.STR.30.4.736
33. L.R. Loehr, W.D. Rosamond, P.P. Chang, and et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study) Am J Cardiol 101 7 2008 1016 1022 10.1016/j.amjcard.2007.11.061
34. J.A.H. Baecke, J. Burema, and J.E.R. Frijters A short questionnaire for the measurement of habitual physical activity in epidemiological studies Am J Clin Nutr 36 5 1982 936 942
35. P.M. Ridker Cardiology patient page. C-reactive protein: a simple test to help predict risk of heart attack and stroke Circulation 108 12 2003 e81 e85 10.1161/01.CIR.0000093381.57779.67
36. V.C. Luft, M.I. Schmidt, J.S. Pankow, and et al. Chronic inflammation role in the obesity-diabetes association: a case-cohort study Diabetol Metab Syndr 5 1 2013 31 10.1186/1758-5996-5-31
37. B.B. Duncan, M.I. Schmidt, L.E. Chambless, and et al. Fibrinogen, other putative markers of inflammation, and weight gain in middle-aged adults - the ARIC study. Atherosclerosis Risk in Communities Obes Res 8 4 2000 279 286 10.1038/oby.2000.33
38. E.M. DeGoma, B. French, R.L. Dunbar, and et al. Intraindividual variability of C-reactive protein: the Multi-Ethnic Study of Atherosclerosis Atherosclerosis 224 1 2012 274 279 10.1016/j.atherosclerosis.2012.07.017
39. J.K. Bower, M. Lazo, S.P. Juraschek, and et al. Within-person variability in high-sensitivity C-reactive protein Arch Intern Med 172 19 2012 1519 1521 10.1001/archinternmed.2012.3712
40. S. Wu, Y. Li, C. Jin, and et al. Intra-individual variability of high-sensitivity C-reactive protein in Chinese general population Int J Cardiol 157 1 2012 75 79 10.1016/j.ijcard.2010.12.019
41. J.R. Kizer, A.M. Arnold, N.S. Jenny, and et al. Longitudinal changes in adiponectin and inflammatory markers and relation to survival in the oldest old: the Cardiovascular Health Study All Stars study J Gerontol A Biol Sci Med Sci 66 10 2011 1100 1107 10.1093/gerona/glr098
42. N.S. Jenny, B. French, A.M. Arnold, and et al. Long-term assessment of inflammation and healthy aging in late life: the Cardiovascular Health Study All Stars J Gerontol A Biol Sci Med Sci 67 9 2012 970 976 10.1093/gerona/glr261
43. D.E. Alley, E. Crimmins, K. Bandeen-Roche, and et al. Three-year change in inflammatory markers in elderly people and mortality: the Invecchiare in Chianti study J Am Geriatr Soc 55 11 2007 1801 1807 10.1111/j.1532-5415.2007.01390.x
44. A.G. Tabák, M. Kivimäki, E.J. Brunner, and et al. Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: the Whitehall II study Eur J Endocrinol 163 1 2010 89 95 10.1530/EJE-10-0277